Topic Collection Search
Allergy and immunology
Complementary medicine and alternative therapies
Critical care / intensive care
Dentistry / oral medicine
Geriatric medicine / aging
Haematology / blood transfusion
History of medicine
Legal and forensic medicine
Nutrition and metabolism
Obstetrics and gynaecology
Occupational and environmental medicine
Organisation of health care
Otolaryngology / head and neck surgery
Pharmacology and therapeutics
Primary care, family medicine
Psychiatry and psychotherapy
Quality of care
Statistics and research methods
These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.
A Swiss panel of experts met for the Dementia Summit in Brunnen, Switzerland, to discuss the latest scientific findings on basic and clinical research, as well as practical and political approaches to the challenges of dementia disorders in Switzerland. Here, they present the conference summary.
Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
Encephalitis should be suspected in patients treated with immune checkpoint inhibitors who present with rapidly evolving confusion. Blood tests, CSF analysis, cerebral MRI and an EEG should be performed. Therapy with intravenous corticosteroids is recommended. Steroid unresponsiveness is rare and should lead to a review of the diagnosis. Alternative treatment options are IVIG, plasma exchange therapy and rituximab.
Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult
Multisystem inflammatory syndrome associated with SARS-CoV-2 can occur in adults. The clinical presentation can include severe organ damage with features of incomplete or complete Kawasaki disease, including coronary aneurysm, as well as myocarditis-associated cardiogenic shock and also mononeuritis multiplex.
Homonymous visual field defects in patients with multiple sclerosis: results of computerised perimetry and optical coherence tomography
Homonymous visual field defects can be the first manifestation of multiple sclerosis and have a relatively good prognosis. The incidence of HVFD in multiple sclerosis is unknown, as it is probably underdiagnosed.
The placebo effect represents an elegant model to understand how the brain works. It is worth knowing that there is not a single but many placebo effects, with different mechanisms across different systems, medical conditions and therapeutic interventions.
This short review summarises important new insights into the interaction between these two cell populations and outlines recent observations regarding how memory B cells activate brain-homing autoreactive T cells in multiple sclerosis.
The cellular prion protein (PrPC), a cell surface glycoprotein originally identified for its central role in prion diseases, has recently been implicated in the pathogenesis of other neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. This article provides an overview of what is known about the role of PrPC beyond prion disorders and discusses the potential implications of targeting this protein in different diseases.